London ON – (October 30, 2006) Viron Therapeutics Inc. was announced today as the next recipient of the Featured Company Award presented by the London Economic Development Corporation (LEDC) and the City of London.
Viron is a clinical stage biopharmaceutical company and a world leader in developing a completely new class of medicines to treat inflammatory-based diseases. Located in the Stiller Centre for technology Commercialization, Viron is focused on the development of therapeutics derived from viral proteins as a sustainable and unexploited source of novel drugs. The company identifies and develops powerful protein therapeutics to regulate the body’s inflammatory responses and promote healing.
Originally spun out of the Robarts Research Institute, the company currently employs 20 individuals at its laboratory facility in London and draws on the expertise of collaborators across North America and Europe.
We are pleased to be selected by the London Economic Development Corporation for the “Featured Company of London Award,” said Neil K. Warma, Viron’s President and Chief Executive Officer. “Viron became part of the London business community in1997 and has been steadily advancing its novel drug development platform since that time. Viron is now internationally recognized as a leader in developing novel medicines targeting inflammation and its lead compound, VT-111 was recently named one of the top 10 most promising cardiovascular drugs in development.”
Viron is currently treating patients in a phase 2 clinical trial, with the ultimate goal of significantly reducing heart attacks and death in patients with heart disease. Viron is also developing medicines to treat such debilitating diseases as organ rejection in transplant patients, rheumatoid arthritis and inflammatory bowel disease.
Committed to translating innovative research ideas into life-saving treatments Viron was recognized for its achievements as the 2005 Canadian recipient of the prestigious Prix Galien for Biotechnology and the 2005 recipient of the London Chamber of Commerce Product Innovation Award.
Neil K. Warma, Dennis Ensing, Chief Financial Officer and Carol Barrett, Manager, Operations will be on hand to receive a commemorative plaque from Mayor Anne Marie DeCicco-Best at the City council meeting on November 6.
-30-
For more information, please contact:
Neil Warma
President and Chief Executive Officer
Viron Therapeutics
Ph: (519) 858-5109
Lesley Cornelius
Director, Business Development, Life Sciences
London Economic Development Corporation
Ph: 519-661-5010
Viron is a clinical stage biopharmaceutical company and a world leader in developing a completely new class of medicines to treat inflammatory-based diseases. Located in the Stiller Centre for technology Commercialization, Viron is focused on the development of therapeutics derived from viral proteins as a sustainable and unexploited source of novel drugs. The company identifies and develops powerful protein therapeutics to regulate the body’s inflammatory responses and promote healing.
Originally spun out of the Robarts Research Institute, the company currently employs 20 individuals at its laboratory facility in London and draws on the expertise of collaborators across North America and Europe.
We are pleased to be selected by the London Economic Development Corporation for the “Featured Company of London Award,” said Neil K. Warma, Viron’s President and Chief Executive Officer. “Viron became part of the London business community in1997 and has been steadily advancing its novel drug development platform since that time. Viron is now internationally recognized as a leader in developing novel medicines targeting inflammation and its lead compound, VT-111 was recently named one of the top 10 most promising cardiovascular drugs in development.”
Viron is currently treating patients in a phase 2 clinical trial, with the ultimate goal of significantly reducing heart attacks and death in patients with heart disease. Viron is also developing medicines to treat such debilitating diseases as organ rejection in transplant patients, rheumatoid arthritis and inflammatory bowel disease.
Committed to translating innovative research ideas into life-saving treatments Viron was recognized for its achievements as the 2005 Canadian recipient of the prestigious Prix Galien for Biotechnology and the 2005 recipient of the London Chamber of Commerce Product Innovation Award.
Neil K. Warma, Dennis Ensing, Chief Financial Officer and Carol Barrett, Manager, Operations will be on hand to receive a commemorative plaque from Mayor Anne Marie DeCicco-Best at the City council meeting on November 6.
-30-
For more information, please contact:
Neil Warma
President and Chief Executive Officer
Viron Therapeutics
Ph: (519) 858-5109
Lesley Cornelius
Director, Business Development, Life Sciences
London Economic Development Corporation
Ph: 519-661-5010
